Skip to main content
Figure 2 | Arthritis Research & Therapy

Figure 2

From: Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies

Figure 2

Estimated proportion of patients with relapse of upper gastrointestinal symptoms. Kaplan-Meier life-table analyses of the proportion of patients with relapse of pain, discomfort, or burning in the upper abdomen throughout 6 months of treatment with esomeprazole 20 mg (E20), esomeprazole 40 mg (E40), or placebo (a) for all patients, (b) according to treatment in the acute and maintenance studies, (c) for non-selective non-steroidal anti-inflammatory drug (NSAID) users, and (d) for selective cyclo-oxygenase-2 (COX-2) NSAID users (pooled intention-to-treat population). Diary card data were not available for 10 patients (placebo, n = 2; esomeprazole 20 mg, n = 6; esomeprazole 40 mg, n = 2). §p = 0.006, ¥p = 0.001, ‡p = 0.03, *p = 0.02, p = 0.08, †p = 0.01, all versus placebo. CI, confidence interval.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us